S-adenosyl methionine improves motor co-ordination with reduced oxidative stress, dopaminergic neuronal loss, and DNA methylation in the brain striatum of 6-hydroxydopamine-induced neurodegeneration in rats.

Autor: Jalgaonkar S; Department of Pharmacology & Therapeutics, Seth G. S. Medical College and King Edward Memorial Hospital, Mumbai, India., Gajbhiye S; Department of Pharmacology & Therapeutics, Seth G. S. Medical College and King Edward Memorial Hospital, Mumbai, India., Sayyed M; Department of Pharmacology & Therapeutics, Seth G. S. Medical College and King Edward Memorial Hospital, Mumbai, India., Tripathi R; Department of Pharmacology & Therapeutics, Seth G. S. Medical College and King Edward Memorial Hospital, Mumbai, India., Khatri N; Department of Pharmacology & Therapeutics, Seth G. S. Medical College and King Edward Memorial Hospital, Mumbai, India., Parmar U; Department of Pharmacology & Therapeutics, Seth G. S. Medical College and King Edward Memorial Hospital, Mumbai, India., Shankar A; Department of Pharmacology & Therapeutics, Seth G. S. Medical College and King Edward Memorial Hospital, Mumbai, India.
Jazyk: angličtina
Zdroj: Anatomical record (Hoboken, N.J. : 2007) [Anat Rec (Hoboken)] 2023 Apr; Vol. 306 (4), pp. 820-830. Date of Electronic Publication: 2022 May 10.
DOI: 10.1002/ar.24948
Abstrakt: Purpose: Parkinson's disease (PD) is the most common age-related neurodegenerative disease worldwide. S-adenosyl methionine (SAMe), a methyl donor that plays an important role in DNA methylation, could replenish the cellular antioxidant glutathione (GSH). Herein, we investigated the neuroprotective effects of SAMe in 6-hydroxydopamine (6-OHDA) rat models of PD and elucidated the underlying mechanism.
Methods: PD model rats were developed by injecting 6-OHDA stereotaxically into the striatum. In Phase 1 of the study, we performed the neurobehavioral tests, GSH assay, and histopathology to evaluate the neuroprotective effects of SAMe. The animals were treated with SAMe (150 or 300 mg/kg body weight) orally for 28 days. The positive control group received selegiline (5 mg/kg), whereas the disease control group received normal saline. In Phase 2, we evaluated the striatal dopamine levels and performed DNA methylation assay to uncover the mechanism of action of SAMe. In this phase, a higher dose of SAMe (300 mg/kg) was used.
Results: SAMe (300 mg/kg) treatment for 4 weeks significantly attenuated the abnormal circling behavior in PD rats (p < 0.05). Moreover, SAMe at both doses (150 and 300 mg/kg) enhanced the performance of PD rats in the open field test and stepping test (p < 0.05). SAMe treatment significantly increased the GSH levels, and at high dose, SAMe restricted neuronal loss in the striatum of PD-model rats (p < 0.05). Moreover, SAMe treatment led to a significant recovery in the dopamine levels and improved the DNA methylation status in the dopaminergic neurons (p < 0.05) of PD model rats.
Conclusion: SAMe exhibits antioxidant activity and DNA methylation modulating effects in 6-OHDA model PD rats. Moreover, SAMe prevents neuronal loss in PD rats suggesting that SAMe has therapeutic potential in preventing PD development. The neuroprotective potential of SAMe is greater at high doses.
(© 2022 American Association for Anatomy.)
Databáze: MEDLINE
Externí odkaz: